Skip to content
OpenCapital
Get started

Exelixis EXEL Discounts and allowances — Total revenues

Other product segments

Gross product revenues
$795.35M+10.2%
License revenues
$56.95M+34.1%
Collaboration
$55.84M+32.4%
Collaboration services revenues
-$3.96M-211%

Similar metrics at other companies

Madrigal Pharmaceuticals, Inc. logo
MDGLRebates, Customer Fees/Credits, Co-Pay Assistance, and Other — Gross To Net Adjustments Reserve
$90.5M+317%
Madrigal Pharmaceuticals, Inc. logo
MDGLChargebacks, Discounts for Prompt Pay and Other Allowances — Gross To Net Adjustments Reserve
$20.83M+363%
Madrigal Pharmaceuticals, Inc. logo
MDGLRebates, Customer Fees/Credits, Co-Pay Assistance, and Other — Provision related to sales in the current year
$80.57M+818%
Madrigal Pharmaceuticals, Inc. logo
MDGLRebates, Co-Pay Assistance, Returns, and Other — Gross To Net Adjustments Reserve
$122.73M—
Neurocrine Biosciences logo
NBIXNet product sales — Total revenues
$811M+43.9%
Madrigal Pharmaceuticals, Inc. logo
MDGLRebates, Customer Fees/Credits, Co-Pay Assistance, and Other — Gross To Net Adjustments Reserve Credits And Payments Made
$71.98M+2,047%

Other financials

Income statement

See full
Revenue$610.8M+10.0%
Gross profit$590.9M+10.2%
Operating income$251.3M+34.5%
Net income$210.5M+31.9%
EPS (diluted)$0.79+43.6%

Balance sheet

See full
Cash & equivalents$226.2M+23.1%
Total debt$169.5M-9.4%
Total equity$1.9B-9.2%
Total assets$2.6B-8.6%

Cash flow

See full
Operating cash flow$251.8M+19.1%
CapEx$1.5M-48.9%
Free cash flow$250.3M+20.1%

Valuation

See full
Market cap$13.05B+10.1%
Enterprise value$12.99B+9.5%
P/E15.7×-2.8×
P/S5.5×+0.3×

Profitability

See full
Gross margin96.4%-0.3pp
Operating margin39.4%+6.3pp
Net margin35.1%+7.1pp
FCF margin38.6%+2.9pp

Returns & leverage

See full
Return on equity41%+10.8pp
Debt / equity0.1×0.0×
Current ratio3.3×-0.2×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's discounts and allowances — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exelixis's discounts and allowances — total revenues?
Exelixis (EXEL) reported discounts and allowances — total revenues of -$240.38M in Q1 2026.
How has Exelixis's discounts and allowances — total revenues changed year-over-year?
Exelixis's discounts and allowances — total revenues decreased by 15.3% year-over-year, from -$208.43M to -$240.38M.
What is the long-term trend for Exelixis's discounts and allowances — total revenues?
Over 4 years (2021 to 2025), Exelixis's discounts and allowances — total revenues has grown at a 24.0% compound annual growth rate (CAGR), from -$375.66M to -$889M.
What does discounts and allowances — total revenues mean?
The total amount of price reductions, rebates, and returns subtracted from gross sales to determine net revenue.
How do you interpret discounts and allowances — total revenues?
An increase in this metric relative to gross sales suggests higher pricing pressure, increased utilization of patient assistance programs, or more aggressive managed care contracting, which may compress net margins. Conversely, a decrease may indicate improved pricing power or a shift in the payer mix toward more profitable channels.
How does discounts and allowances — total revenues compare across companies?
Most biopharmaceutical companies report these as 'Gross-to-Net' adjustments, and investors typically compare these as a percentage of gross sales to evaluate the efficiency of commercialization strategies against industry peers.